Jamie Findlow

Summary

Affiliation: Health Protection Agency
Country: UK

Publications

  1. ncbi request reprint Neisseria vaccines 2007
    Jamie Findlow
    Vaccine Evaluation Unit, Health Protection Agency North West, Manchester Laboratory, Manchester Medical Microbiology Partnership, Manchester Royal Infirmary, Manchester, M13 9WZ, UK
    Expert Rev Vaccines 6:485-9. 2007
  2. pmc Age-stratified prevalences of pneumococcal-serotype-specific immunoglobulin G in England and their relationship to the serotype-specific incidence of invasive pneumococcal disease prior to the introduction of the pneumococcal 7-valent conjugate vaccine
    Paul Balmer
    Vaccine Evaluation Unit, Health Protection Agency, Manchester Laboratory, Clinical Sciences Building 2, Manchester Royal Infirmary, Oxford Road, Manchester, United Kingdom M13 9WZ
    Clin Vaccine Immunol 14:1442-50. 2007
  3. pmc Persistence of antibodies in laboratory staff immunized with quadrivalent meningococcal polysaccharide vaccine
    Johannes Elias
    Institute for Hygiene and Microbiology, University of Wuerzburg, Josef Schneider Strasse 2, 97080, Wuerzburg, Germany
    J Occup Med Toxicol 8:4. 2013
  4. doi request reprint Multicenter, open-label, randomized phase II controlled trial of an investigational recombinant Meningococcal serogroup B vaccine with and without outer membrane vesicles, administered in infancy
    Jamie Findlow
    Vaccine Evaluation Unit, Health Protection Agency North West, Manchester Royal Infirmary, Manchester, UK
    Clin Infect Dis 51:1127-37. 2010
  5. pmc Inadequacy of colominic acid as an absorbent intended to facilitate use of complement-preserved baby rabbit serum in the Neisseria meningitidis serogroup B serum bactericidal antibody assay
    Jamie Findlow
    Vaccine Evaluation Unit, Health Protection Agency North West, Manchester Laboratory, Manchester Medical Microbiology Partnership, Manchester Royal Infirmary, Manchester M13 9WZ, United Kingdom
    Clin Vaccine Immunol 14:556-61. 2007
  6. pmc Comparison of phenotypically indistinguishable but geographically distinct Neisseria meningitidis Group B isolates in a serum bactericidal antibody assay
    Jamie Findlow
    Vaccine Evaluation Unit, Health Protection Agency North West, Manchester Laboratory, Manchester Medical Microbiology Partnership, Clinical Sciences Building II, Manchester Royal Infirmary, Manchester, M13 9WZ, United Kingdom
    Clin Vaccine Immunol 14:1451-7. 2007
  7. pmc Comparison and correlation of neisseria meningitidis serogroup B immunologic assay results and human antibody responses following three doses of the Norwegian meningococcal outer membrane vesicle vaccine MenBvac
    Jamie Findlow
    Vaccine Evaluation Unit, Health Protection Agency North West, Manchester Laboratory, Manchester Medical Microbiology Partnership, Manchester Royal Infirmary, Manchester, United Kingdom
    Infect Immun 74:4557-65. 2006
  8. ncbi request reprint Effect of sequence variation in meningococcal PorA outer membrane protein on the effectiveness of a hexavalent PorA outer membrane vesicle vaccine in toddlers and school children
    Jamie Findlow
    Vaccine Evaluation Department, Health Protection Agency North West, Manchester Laboratory, Manchester Medical Microbiology Partnership, Manchester Royal Infirmary, Manchester, M13 9WZ, UK
    Vaccine 23:2623-7. 2005
  9. pmc Characterization of fHbp, nhba (gna2132), nadA, porA, and sequence type in group B meningococcal case isolates collected in England and Wales during January 2008 and potential coverage of an investigational group B meningococcal vaccine
    Jay Lucidarme
    Vaccine Evaluation Unit, Health Protection Agency, P O Box 209, Floor 2, Clinical Sciences Building 2, Manchester Royal Infirmary, Oxford Road, Manchester M139WZ, United Kingdom
    Clin Vaccine Immunol 17:919-29. 2010
  10. pmc Kinetics of antibody persistence following administration of a combination meningococcal serogroup C and haemophilus influenzae type b conjugate vaccine in healthy infants in the United Kingdom primed with a monovalent meningococcal serogroup C vaccine
    Ray Borrow
    Vaccine Evaluation Unit, Health Protection Agency, Manchester Medical Microbiology Partnership, P O Box 209, Clinical Sciences Building 2, Manchester Royal Infirmary, Manchester M13 9WZ, United Kingdom
    Clin Vaccine Immunol 17:154-9. 2010

Collaborators

Detail Information

Publications26

  1. ncbi request reprint Neisseria vaccines 2007
    Jamie Findlow
    Vaccine Evaluation Unit, Health Protection Agency North West, Manchester Laboratory, Manchester Medical Microbiology Partnership, Manchester Royal Infirmary, Manchester, M13 9WZ, UK
    Expert Rev Vaccines 6:485-9. 2007
  2. pmc Age-stratified prevalences of pneumococcal-serotype-specific immunoglobulin G in England and their relationship to the serotype-specific incidence of invasive pneumococcal disease prior to the introduction of the pneumococcal 7-valent conjugate vaccine
    Paul Balmer
    Vaccine Evaluation Unit, Health Protection Agency, Manchester Laboratory, Clinical Sciences Building 2, Manchester Royal Infirmary, Oxford Road, Manchester, United Kingdom M13 9WZ
    Clin Vaccine Immunol 14:1442-50. 2007
    ..These data provide a baseline for natural immunity to the pneumococcal serotypes analyzed prior to the introduction of pneumococcal conjugate vaccine in the United Kingdom...
  3. pmc Persistence of antibodies in laboratory staff immunized with quadrivalent meningococcal polysaccharide vaccine
    Johannes Elias
    Institute for Hygiene and Microbiology, University of Wuerzburg, Josef Schneider Strasse 2, 97080, Wuerzburg, Germany
    J Occup Med Toxicol 8:4. 2013
    ..While, until recently, immunization with quadrivalent polysaccharide vaccine represented one cornerstone of protection, data on long-term persistence of antibodies in adults remain scarce...
  4. doi request reprint Multicenter, open-label, randomized phase II controlled trial of an investigational recombinant Meningococcal serogroup B vaccine with and without outer membrane vesicles, administered in infancy
    Jamie Findlow
    Vaccine Evaluation Unit, Health Protection Agency North West, Manchester Royal Infirmary, Manchester, UK
    Clin Infect Dis 51:1127-37. 2010
    ..7-2,4). In this trial, we assessed the immunogenicity of these formulations in infants, who are at greatest risk of contracting MenB disease...
  5. pmc Inadequacy of colominic acid as an absorbent intended to facilitate use of complement-preserved baby rabbit serum in the Neisseria meningitidis serogroup B serum bactericidal antibody assay
    Jamie Findlow
    Vaccine Evaluation Unit, Health Protection Agency North West, Manchester Laboratory, Manchester Medical Microbiology Partnership, Manchester Royal Infirmary, Manchester M13 9WZ, United Kingdom
    Clin Vaccine Immunol 14:556-61. 2007
    ..However, alternative absorbents, such as purified MenB polysaccharide, may warrant further evaluation...
  6. pmc Comparison of phenotypically indistinguishable but geographically distinct Neisseria meningitidis Group B isolates in a serum bactericidal antibody assay
    Jamie Findlow
    Vaccine Evaluation Unit, Health Protection Agency North West, Manchester Laboratory, Manchester Medical Microbiology Partnership, Clinical Sciences Building II, Manchester Royal Infirmary, Manchester, M13 9WZ, United Kingdom
    Clin Vaccine Immunol 14:1451-7. 2007
    ..These results have implications for the choice of MenB target strains for inclusion in future studies of MenB vaccines and highlight the requirement for standardization of target strains between laboratories...
  7. pmc Comparison and correlation of neisseria meningitidis serogroup B immunologic assay results and human antibody responses following three doses of the Norwegian meningococcal outer membrane vesicle vaccine MenBvac
    Jamie Findlow
    Vaccine Evaluation Unit, Health Protection Agency North West, Manchester Laboratory, Manchester Medical Microbiology Partnership, Manchester Royal Infirmary, Manchester, United Kingdom
    Infect Immun 74:4557-65. 2006
    ..These results emphasize the need for standardized methodologies that would allow a more robust comparison of assays between laboratories and promote their further evaluation as correlates of protection against MenB disease...
  8. ncbi request reprint Effect of sequence variation in meningococcal PorA outer membrane protein on the effectiveness of a hexavalent PorA outer membrane vesicle vaccine in toddlers and school children
    Jamie Findlow
    Vaccine Evaluation Department, Health Protection Agency North West, Manchester Laboratory, Manchester Medical Microbiology Partnership, Manchester Royal Infirmary, Manchester, M13 9WZ, UK
    Vaccine 23:2623-7. 2005
    ..This was also reflected when > or = 4-fold rises in SBA titres were examined. This finding in sera from toddlers and school children may have implications for PorA based vaccines...
  9. pmc Characterization of fHbp, nhba (gna2132), nadA, porA, and sequence type in group B meningococcal case isolates collected in England and Wales during January 2008 and potential coverage of an investigational group B meningococcal vaccine
    Jay Lucidarme
    Vaccine Evaluation Unit, Health Protection Agency, P O Box 209, Floor 2, Clinical Sciences Building 2, Manchester Royal Infirmary, Oxford Road, Manchester M139WZ, United Kingdom
    Clin Vaccine Immunol 17:919-29. 2010
    ..On the basis of genotypic data and predicted immunological cross-reactivity, the potential level of rMenB-OMV vaccine coverage in England and Wales ranges from 66% to 100%...
  10. pmc Kinetics of antibody persistence following administration of a combination meningococcal serogroup C and haemophilus influenzae type b conjugate vaccine in healthy infants in the United Kingdom primed with a monovalent meningococcal serogroup C vaccine
    Ray Borrow
    Vaccine Evaluation Unit, Health Protection Agency, Manchester Medical Microbiology Partnership, P O Box 209, Clinical Sciences Building 2, Manchester Royal Infirmary, Manchester M13 9WZ, United Kingdom
    Clin Vaccine Immunol 17:154-9. 2010
    ....
  11. doi request reprint Immunogenicity of a single dose of meningococcal group C conjugate vaccine given at 3 months of age to healthy infants in the United kingdom
    Helen Findlow
    Vaccine Evaluation Unit, Health Protection Agency, Manchester Medical Microbiology Partnership, Manchester Royal Infirmary, Manchester, United Kingdom
    Pediatr Infect Dis J 31:616-22. 2012
    ..Recent data have demonstrated that 2 of the 3 MCC vaccines showed potential for use as a single priming dose in infancy...
  12. pmc Molecular targets in meningococci: efficient routine characterization and optimal outbreak investigation in conjunction with routine surveillance of the meningococcal group B vaccine candidate, fHBP
    Jay Lucidarme
    Vaccine Evaluation Unit, Health Protection Agency, PO Box 209, Floor 2, Clinical Sciences Building 2, Manchester Royal Infirmary, Oxford Road, Manchester M13 9WZ, United Kingdom
    Clin Vaccine Immunol 18:194-202. 2011
    ....
  13. doi request reprint Genetic Distribution of Noncapsular Meningococcal Group B Vaccine Antigens in Neisseria lactamica
    Jay Lucidarme
    Vaccine Evaluation Unit, Public Health England, Manchester, United Kingdom
    Clin Vaccine Immunol 20:1360-9. 2013
    ..Thus, 4CMenB vaccine responses may impact or be impacted by nasopharyngeal carriage of commensal neisseriae. This highlights an area for further research and surveillance should the vaccine be routinely implemented. ..
  14. pmc Characterization of Neisseria meningitidis isolates that do not express the virulence factor and vaccine antigen factor H binding protein
    Jay Lucidarme
    Vaccine Evaluation Unit, Health Protection Agency, North West Regional Laboratory, P O Box 209, Clinical Sciences Building II, Manchester Royal Infirmary, Manchester M13 9WZ, United Kingdom
    Clin Vaccine Immunol 18:1002-14. 2011
    ..No fH binding was detected to other ligands among the fHbp-negative strains. The implications of these findings for meningococcal pathogenesis and prevention are discussed...
  15. doi request reprint Recombinant protein meningococcal serogroup B vaccine combined with outer membrane vesicles
    Xilian Bai
    Vaccine Evaluation Unit, Health Protection Agency North West, Manchester Medical Microbiology Partnership, Manchester Royal Infirmary, Manchester, M13 9WZ, UK
    Expert Opin Biol Ther 11:969-85. 2011
    ..The novel vaccine Bexsero (previously 4CMenB) has been developed and proven safe and immunogenic in clinical trials...
  16. pmc Interlaboratory standardization of the measurement of serum bactericidal activity by using human complement against meningococcal serogroup b, strain 44/76-SL, before and after vaccination with the Norwegian MenBvac outer membrane vesicle vaccine
    Ray Borrow
    Meningococcal Reference Unit, HPA North West Laboratory, P O Box 209, Manchester Royal Infirmary, Manchester M13 9WZ, United Kingdom
    Clin Diagn Lab Immunol 12:970-6. 2005
    ..The SBA assay has been harmonized between the four different laboratories with good agreement on seroconversion rates, n-fold changes in titers, and percentages of subjects with SBA titers of >or=4...
  17. doi request reprint Prevention of meningococcal serogroup C disease by NeisVac-C
    Ray Borrow
    Vaccine Evaluation Unit, Health Protection Agency North West, PO Box 209, Clinical Sciences Building 2, Manchester Royal Infirmary, Manchester, M13 9WZ, UK
    Expert Rev Vaccines 8:265-79. 2009
    ..NeisVac-C also enhances tetanus toxid responses and a dose of NeisVac-C in older children induces responses similar to a dose of tetanus toxoid vaccine...
  18. pmc Characterization of fHbp, nhba (gna2132), nadA, porA, sequence type (ST), and genomic presence of IS1301 in group B meningococcal ST269 clonal complex isolates from England and Wales
    Jay Lucidarme
    Vaccine Evaluation Unit, Health Protection Agency, P O Box 209, Floor 2, Clinical Sciences Building 2, Manchester Royal Infirmary, Oxford Road, Manchester M13 9WZ, United Kingdom
    J Clin Microbiol 47:3577-85. 2009
    ..Expression studies and serum bactericidal antibody assays will serve to enhance predictions of coverage and will augment ongoing studies regarding the significance of IS1301 within the ST269 cluster...
  19. ncbi request reprint Characterization of the key antigenic components and pre-clinical immune responses to a meningococcal disease vaccine based on Neisseria lactamica outer membrane vesicles
    Michelle Finney
    Health Protection Agency, Centre for Emergency Preparedness and Response, Porton Down, Salisbury, UK
    Hum Vaccin 4:23-30. 2008
    ..However, such antisera did mediate opsonophagocytosis, suggestingthat this may did mediate opsonophagocytosis, suggesting that this may be a mechanism by which this vaccine protects in a mouse model of meningococcal bacteraemia...
  20. pmc Phase I safety and immunogenicity study of a candidate meningococcal disease vaccine based on Neisseria lactamica outer membrane vesicles
    Andrew R Gorringe
    Health Protection Agency, Centre for Emergency Preparedness and Response, Porton Down, Salisbury, UK
    Clin Vaccine Immunol 16:1113-20. 2009
    ..In conclusion, this N. lactamica OMV vaccine is safe and induces a weak but broad humoral immune response to N. meningitidis...
  21. doi request reprint Mucosal immunity in healthy adults after parenteral vaccination with outer-membrane vesicles from Neisseria meningitidis serogroup B
    Victoria Davenport
    Cellular and Molecular Medicine, School of Medical Sciences, University of Bristol, Bristol, United Kingdom
    J Infect Dis 198:731-40. 2008
    ..This natural immunity is associated with mucosal and systemic T cell memory. Whether parenteral Neisseria meningitidis serogroup B (MenB) vaccination influences natural mucosal immunity is unknown...
  22. pmc Seroprevalence of bactericidal and anti-outer membrane vesicle antibodies to Neisseria meningitidis group B in England
    Caroline Trotter
    Department of Social Medicine, University of Bristol, Canynge Hall, Whiteladies Road, Bristol BS8 2PR, United Kingdom
    Clin Vaccine Immunol 14:863-8. 2007
    ..With the exception of children aged 3 to 11 months, there was no clear relationship between disease incidence and seroprevalence...
  23. pmc Immunogenicity and safety of three doses of a bivalent (B:4:p1.19,15 and B:4:p1.7-2,4) meningococcal outer membrane vesicle vaccine in healthy adolescents
    Dominique Boutriau
    GlaxoSmithKline Biologicals, Rue de l Institut 89, 1330 Rixensart, Belgium
    Clin Vaccine Immunol 14:65-73. 2007
    ....
  24. ncbi request reprint Evidence for naturally acquired T cell-mediated mucosal immunity to Neisseria meningitidis
    Victoria Davenport
    Department of Pathology and Microbiology, School of Medical Sciences, University of Bristol, Bristol, United Kingdom
    J Immunol 171:4263-70. 2003
    ..This mucosal cellular immunity can be present in the absence of serum bactericidal Abs, a classical marker of protective immunity...
  25. pmc Effect of vaccination with carrier protein on response to meningococcal C conjugate vaccines and value of different immunoassays as predictors of protection
    Moya Burrage
    Centre for Applied Microbiology and Research, Porton Down, Salisbury, Wiltshire, United Kingdom
    Infect Immun 70:4946-54. 2002
    ....
  26. ncbi request reprint On the neisserial vaccine quest: Neisseria Vaccines 2007
    Rolando Pajon
    Meningococcal Research Department, Center for Genetic Engineering and Biotechnology, Cubanacán Havana, Cuba
    Expert Rev Anti Infect Ther 5:545-50. 2007